Keeps Biopharma KRX:256940KOSDAQ
킵스파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days3
DART filings, 7 days1
Articles tracked3since Sep 11
In Q2 2026, Keeps Biopharma reported revenue of ₩74.9bn, up 72.8% year on year, and an operating loss of ₩2.4bn. Keeps Biopharma (킵스파마) appeared in 3 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 14 with 3 articles. The most common catalyst was clinical & approvals (1).
Keeps Biopharma quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩74.9bn | +72.8% | −₩2.4bn | −₩9.0bn |
| Q1 2026 | ₩59.4bn | +46.2% | −₩664m | ₩5.7bn |
| Q4 2025 derived | ₩45.2bn | +37.7% | ₩1.0bn | −₩9.2bn |
| Q3 2025 | ₩40.9bn | +29.8% | ₩1.4bn | −₩446m |
| Q2 2025 | ₩43.3bn | +37.6% | −₩976m | ₩718m |
| Q1 2025 | ₩40.6bn | +28.2% | ₩89m | −₩1.4bn |
| Q4 2024 derived | ₩32.8bn | +5.9% | −₩1.3bn | ₩1.4bn |
| Q3 2024 | ₩31.5bn | +29.8% | ₩1.0bn | −₩1.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Keeps Biopharma top stories 2 weeks, by number of outlets
- 1
- 2
- 3
